GB2612411A - Novel medicinal compound for combating viral infections like corona virus infection and method of mitigating the conditions - Google Patents
Novel medicinal compound for combating viral infections like corona virus infection and method of mitigating the conditions Download PDFInfo
- Publication number
- GB2612411A GB2612411A GB2211869.9A GB202211869A GB2612411A GB 2612411 A GB2612411 A GB 2612411A GB 202211869 A GB202211869 A GB 202211869A GB 2612411 A GB2612411 A GB 2612411A
- Authority
- GB
- United Kingdom
- Prior art keywords
- medicinal compound
- novel medicinal
- compound
- viral infections
- egcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is a medicinal compound that contains two ingredients that are available in organic products. The compound to be used in the human body to mitigate conditions due to viral infections. Epigallo Catechin gallate (EGCG) is extracted and mixed with bee-honey to be used as oral solution where EGCG is mixed with alcohol to be used as inhalation compound. Protease in the bee-honey causing the damage to the outer layer of the virus where EGCG is used to destroy the RNA of the virus.
Claims (10)
1. [Claim 1] A novel medicinal compound comprising: Epigallo catechin gallate (EGCG) and protease of bee honey to treat viral infections in the human body.
2. [Claim 2] The novel medicinal compound as claimed in claim 1 characterized in that wherein epigallo catechin is concentrated to 80% above when extracted from tea catechin while removing epicatechin gallate (ECG).
3. [Claim 3] The novel medicinal compound as claimed in claim 1 characterized in that wherein epigallo catechin and protease from bee-honey mixed in the ratio of 3:1 at the temperature range 40 degree Celsius - 45 degree Celsius.
4. [Claim 4] The novel medicinal compound as claimed in claim 3 is recommended 20ml oral dose 3 times a day to effective mitigation and curing of viral invasions in the human body.
5. [Claim 5] A novel medicinal compound comprising: Epigallo catechin gallate (EGCG) and alcohol to treat viral infections in the human body.
6. [Claim 6] The novel medicinal compound as claimed in claim 5 characterized in that wherein epigallo catechin and alcohol is mixed at a pressurized closed environment.
7. [Claim 7] The novel medicinal compound as claimed in claim 5 to be used with patients in critical conditions in mitigating viral infections with humans while taking oral dose of compound claimed in claim 1.
8. [Claim 8] A novel medicinal compound comprising EGCG of tea catechin and protease of bee honey, where in ECG is removed from tea catechin.
9. [Claim 9] Use of novel medicinal compound as claimed in claim 1 to mitigate cancers like brain tumors.
10. [Claim 10] Use of novel medicinal compound as claimed in anyone above in combination as directed by the specialists.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2020/053205 WO2021198739A1 (en) | 2020-04-03 | 2020-04-03 | Novel medicinal compound for combating viral infections like corona virus infection and method of mitigating the conditions |
| CA3092524A CA3092524A1 (en) | 2020-04-03 | 2020-09-09 | A novel compound for combating viral infections, mitigating non-transferable deceases and enhancing the immunity in the human body |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202211869D0 GB202211869D0 (en) | 2022-09-28 |
| GB2612411A true GB2612411A (en) | 2023-05-03 |
Family
ID=77928333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2211869.9A Withdrawn GB2612411A (en) | 2020-04-03 | 2020-04-03 | Novel medicinal compound for combating viral infections like corona virus infection and method of mitigating the conditions |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA3092524A1 (en) |
| GB (1) | GB2612411A (en) |
| WO (1) | WO2021198739A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090170928A1 (en) * | 2005-04-28 | 2009-07-02 | Bruno Ferdinando F | Synthesis of oligo/poly(catechins) and methods of use |
| US20160346308A1 (en) * | 2014-02-07 | 2016-12-01 | Shaker A. Mousa | Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis c infection |
| US20160361291A1 (en) * | 2013-12-18 | 2016-12-15 | Abbott Laboratories | Methods for increasing skeletal muscle protein synthesis using green tea extract |
| US20180177860A1 (en) * | 2015-06-11 | 2018-06-28 | Industry-Academic Cooperation Foundation, Yonsei University | Vaccine containing virus inactivated by green tea extract, and preparation method therefor |
| US20200054595A1 (en) * | 2018-08-17 | 2020-02-20 | Augusta University Research Institute, Inc. | EGCG-Palmitate Compositions and Methods of Use Thereof |
-
2020
- 2020-04-03 GB GB2211869.9A patent/GB2612411A/en not_active Withdrawn
- 2020-04-03 WO PCT/IB2020/053205 patent/WO2021198739A1/en not_active Ceased
- 2020-09-09 CA CA3092524A patent/CA3092524A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090170928A1 (en) * | 2005-04-28 | 2009-07-02 | Bruno Ferdinando F | Synthesis of oligo/poly(catechins) and methods of use |
| US20160361291A1 (en) * | 2013-12-18 | 2016-12-15 | Abbott Laboratories | Methods for increasing skeletal muscle protein synthesis using green tea extract |
| US20160346308A1 (en) * | 2014-02-07 | 2016-12-01 | Shaker A. Mousa | Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis c infection |
| US20180177860A1 (en) * | 2015-06-11 | 2018-06-28 | Industry-Academic Cooperation Foundation, Yonsei University | Vaccine containing virus inactivated by green tea extract, and preparation method therefor |
| US20200054595A1 (en) * | 2018-08-17 | 2020-02-20 | Augusta University Research Institute, Inc. | EGCG-Palmitate Compositions and Methods of Use Thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3092524A1 (en) | 2021-10-03 |
| GB202211869D0 (en) | 2022-09-28 |
| WO2021198739A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| de Carvalho et al. | Evidence-based studies and perspectives of the use of Brazilian green and red propolis in dentistry | |
| CN103156837B (en) | Application of flavonoid in pharmacy | |
| EP2112929B1 (en) | Herbal formulation for wound healing | |
| CN103189065A (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
| WO2002000266A3 (en) | A method of treating and preventing infectious diseases | |
| Gharirvand Eskandari et al. | Medicinal plants with antileishmanial properties: a review study | |
| SE0950390L (en) | System and process for manufacturing a solution with suspended solids and uses therefor | |
| CA3242451A1 (en) | An injectable pharmaceutical composition for the treatment of respiratory diseases in animals | |
| Abo-Neima et al. | Antibacterial and anti-corona virus (229E) activity of Nigella sativa oil combined with photodynamic therapy based on methylene blue in wound infection: in vitro and in vivo study | |
| WO2009099405A2 (en) | Antibacterial compositions and methods of treatment | |
| Pu et al. | Anti-influenza A virus effect of Hypericum perforatum L. extract | |
| Swathi et al. | Protective role of Bacopa monnieri on induced Parkinson’s disease with particular reference to catecholamine system | |
| GB2612411A (en) | Novel medicinal compound for combating viral infections like corona virus infection and method of mitigating the conditions | |
| WO2022135993A3 (en) | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration | |
| CN105250333B (en) | A kind of pharmaceutical composition of antibacterial skin moistening and preparation method thereof | |
| CN104474536A (en) | Fresh agrimonia pilosa medicine preparation for treating wounds | |
| Ullah et al. | Medicinal plants: an insight into wound healing: medicinal plants & wound healing | |
| MX2009006311A (en) | Combination therapy for treating hepatitis c infections. | |
| CN101297866B (en) | Chinese medicament oil solution for treating burn and preparation thereof | |
| CN103202881A (en) | External agent composition for treating rash | |
| CN112426563A (en) | Liquid dressing prepared from myrtle extract and compounding method thereof | |
| US20160113981A1 (en) | Topical composition | |
| MX2022004295A (en) | Therapeutic cannabis extracts. | |
| Rastegarian et al. | In Vivo Assay of Wound Healing Activities of Silymarin Extract on CutaneousWounds Caused by Leishmania major | |
| Rosmalia et al. | Nutmeg (Myristica fragrans) Extracts Accelerate Oral Mucosal Wound Healing In Vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |